amlodipine has been researched along with Innate Inflammatory Response in 26 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2 years) with uncontrolled essential hypertension were randomly assigned to receive olmesartan, an angiotensin II type 1 receptor blocker (ARB) (N = 23), or amlodipine, a calcium channel blocker (CCB) (N = 22), for 6 months." | 9.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 9.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels using amlodipine (5 mg/day) were enrolled in this study." | 9.15 | Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli ( Daida, H; Fukao, K; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miyazaki, T; Ohsaka, H; Shimada, K, 2011) |
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 9.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 9.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 9.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| "Conclusions: The use of quercetin (Corvitin, Quertin) in combination therapy with the combined antihypertensive drug containing ramipril/amlodipine (Egis-Hungary) significantly reduces the levels of nitric oxide, CRP, IL-1, and blood lipid spectrum, which reduces the incidence of complications and progression of hypertension." | 8.12 | INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN. ( Prokosa, MI, 2022) |
| "This study was performed to evaluate the possible protective effect of two calcium channel blocker's "lacidipine (LAC) and amlodipine (AML)" on bone metabolism in an experimental ovariectomized and inflammation-induced osteoporosis rat model (OVXinf)." | 7.83 | Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. ( Albayrak, A; Ayan, AK; Aydin, A; Bayir, Y; Cadirci, E; Demirci, E; Halici, Z; Karakus, E; Ozturk-Karagoz, B; Sahin, A; Unal, D, 2016) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 7.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E-deficient (ApoEKO) mice." | 7.73 | Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. ( Chen, R; Fukunaga, S; Higaki, J; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Mogi, M; Oshita, A; Yoshii, T, 2006) |
| "2 years) with uncontrolled essential hypertension were randomly assigned to receive olmesartan, an angiotensin II type 1 receptor blocker (ARB) (N = 23), or amlodipine, a calcium channel blocker (CCB) (N = 22), for 6 months." | 5.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 5.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "Baseline low-grade inflammation in patients with hypertension was associated with a poor ambulatory BP response, especially with losartan/HCTZ treatment." | 5.17 | Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study. ( Eguchi, K; Fukutomi, M; Hoshide, S; Kario, K; Watanabe, T, 2013) |
| "To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers." | 5.17 | Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels using amlodipine (5 mg/day) were enrolled in this study." | 5.15 | Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli ( Daida, H; Fukao, K; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miyazaki, T; Ohsaka, H; Shimada, K, 2011) |
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 5.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 5.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 5.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| "Conclusions: The use of quercetin (Corvitin, Quertin) in combination therapy with the combined antihypertensive drug containing ramipril/amlodipine (Egis-Hungary) significantly reduces the levels of nitric oxide, CRP, IL-1, and blood lipid spectrum, which reduces the incidence of complications and progression of hypertension." | 4.12 | INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN. ( Prokosa, MI, 2022) |
| "This study was performed to evaluate the possible protective effect of two calcium channel blocker's "lacidipine (LAC) and amlodipine (AML)" on bone metabolism in an experimental ovariectomized and inflammation-induced osteoporosis rat model (OVXinf)." | 3.83 | Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. ( Albayrak, A; Ayan, AK; Aydin, A; Bayir, Y; Cadirci, E; Demirci, E; Halici, Z; Karakus, E; Ozturk-Karagoz, B; Sahin, A; Unal, D, 2016) |
| "We hypothesized that compared with hydrochlorothiazide (HCTZ), the renin inhibitor aliskiren (ALISK) or amlodipine (AMLO) and their combination reduce albuminuria via reduction in renal inflammation, independent of blood pressure (BP) changes." | 3.78 | Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. ( Huang, J; Matavelli, LC; Siragy, HM, 2012) |
| "We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E-deficient (ApoEKO) mice." | 3.73 | Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. ( Chen, R; Fukunaga, S; Higaki, J; Horiuchi, M; Ide, A; Iwai, M; Li, Z; Mogi, M; Oshita, A; Yoshii, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Prokosa, MI | 1 |
| Honda, A | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Bekki, M | 1 |
| Maeda-Ogata, S | 1 |
| Sugiyama, Y | 1 |
| Igata, S | 1 |
| Nishino, Y | 1 |
| Matsui, T | 1 |
| Kurata, S | 1 |
| Abe, T | 1 |
| Yamagishi, SI | 1 |
| Fukumoto, Y | 2 |
| Oh, M | 1 |
| Lee, CW | 1 |
| Ahn, JM | 1 |
| Park, DW | 1 |
| Kang, SJ | 1 |
| Lee, SW | 1 |
| Kim, YH | 1 |
| Moon, DH | 1 |
| Park, SW | 1 |
| Park, SJ | 1 |
| Fukutomi, M | 1 |
| Hoshide, S | 1 |
| Eguchi, K | 1 |
| Watanabe, T | 1 |
| Kario, K | 1 |
| Derosa, G | 4 |
| Cicero, AF | 3 |
| Carbone, A | 3 |
| Querci, F | 3 |
| Fogari, E | 4 |
| D'Angelo, A | 3 |
| Maffioli, P | 3 |
| Takahashi, K | 1 |
| Matsumoto, Y | 1 |
| Do e, Z | 1 |
| Kanazawa, M | 1 |
| Satoh, K | 1 |
| Shimizu, T | 2 |
| Sato, A | 1 |
| Shimokawa, H | 1 |
| Andreeva, AA | 1 |
| Azushima, K | 1 |
| Uneda, K | 1 |
| Tamura, K | 1 |
| Wakui, H | 1 |
| Ohsawa, M | 1 |
| Kobayashi, R | 1 |
| Dejima, T | 1 |
| Kanaoka, T | 1 |
| Maeda, A | 1 |
| Toya, Y | 1 |
| Umemura, S | 1 |
| Karakus, E | 1 |
| Halici, Z | 2 |
| Albayrak, A | 1 |
| Bayir, Y | 1 |
| Demirci, E | 1 |
| Aydin, A | 1 |
| Ozturk-Karagoz, B | 1 |
| Cadirci, E | 2 |
| Ayan, AK | 1 |
| Sahin, A | 1 |
| Unal, D | 1 |
| Lu, J | 1 |
| Liu, F | 1 |
| Chen, F | 1 |
| Jin, Y | 1 |
| Chen, H | 1 |
| Liu, D | 1 |
| Cui, W | 1 |
| Gao, XM | 1 |
| Tsai, A | 1 |
| Al-Sharea, A | 1 |
| Su, Y | 1 |
| Moore, S | 1 |
| Han, LP | 1 |
| Kiriazis, H | 1 |
| Dart, AM | 1 |
| Murphy, AJ | 1 |
| Du, XJ | 1 |
| Suleyman, H | 1 |
| Futai, R | 1 |
| Ito, T | 1 |
| Kawanishi, Y | 1 |
| Terasaki, F | 1 |
| Kitaura, Y | 1 |
| Nakamura, T | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Kawagoe, Y | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Yamagishi, S | 1 |
| Yamada, S | 1 |
| Koide, H | 1 |
| Fukao, K | 1 |
| Shimada, K | 1 |
| Hiki, M | 1 |
| Kiyanagi, T | 1 |
| Hirose, K | 1 |
| Kume, A | 1 |
| Ohsaka, H | 1 |
| Matsumori, R | 1 |
| Kurata, T | 1 |
| Miyazaki, T | 1 |
| Daida, H | 1 |
| Matavelli, LC | 1 |
| Huang, J | 1 |
| Siragy, HM | 1 |
| Toba, H | 1 |
| Nakagawa, Y | 1 |
| Miki, S | 1 |
| Yoshimura, A | 1 |
| Inoue, R | 1 |
| Asayama, J | 1 |
| Kobara, M | 1 |
| Nakata, T | 1 |
| Fogari, R | 1 |
| Preti, P | 1 |
| Zoppi, A | 1 |
| Lazzari, P | 1 |
| Corradi, L | 1 |
| Ciccarelli, L | 1 |
| Yoshii, T | 1 |
| Iwai, M | 1 |
| Li, Z | 1 |
| Chen, R | 1 |
| Ide, A | 1 |
| Fukunaga, S | 1 |
| Oshita, A | 1 |
| Mogi, M | 1 |
| Higaki, J | 1 |
| Horiuchi, M | 1 |
| Doran, DE | 1 |
| Weiss, D | 1 |
| Zhang, Y | 1 |
| Griendling, KK | 1 |
| Taylor, WR | 1 |
| Bakker, EN | 1 |
| Matlung, HL | 1 |
| Bonta, P | 1 |
| de Vries, CJ | 1 |
| van Rooijen, N | 1 |
| Vanbavel, E | 1 |
| Dahl, K | 1 |
| Canetta, PA | 1 |
| D'Agati, VD | 1 |
| Radhakrishnan, J | 1 |
1 review available for amlodipine and Innate Inflammatory Response
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
10 trials available for amlodipine and Innate Inflammatory Response
| Article | Year |
|---|---|
Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2023 |
Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation.
Topics: Amlodipine; Biphenyl Compounds; Calcium Channel Blockers; Carotid Arteries; Carotid Artery Diseases; | 2019 |
Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Res | 2013 |
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Topics: Adipokines; Amlodipine; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Me | 2013 |
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Do | 2014 |
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body M | 2014 |
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Pr | 2009 |
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Atherosclerosis; Biomarkers; Calcium Channel Blocker | 2010 |
Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cross-Ov | 2011 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B | 2006 |
15 other studies available for amlodipine and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Inflammati | 2022 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pres | 2013 |
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Imidazoles; Immune System Diseases; Inf | 2013 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug | 2014 |
Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat.
Topics: Amlodipine; Animals; Bone Density; Calcium Channel Blockers; Collagen Type I; Collagen Type I, alpha | 2016 |
Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Atorvastatin; C-Reactive Protein; Cardiomegaly; Diastole; Heart Ventricl | 2016 |
Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2017 |
Effects of calcium channel blockers on hyaluronidase-induced capillary vascular permeability.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Capillary Permeability; Carrageenan; Dihydropyridines | 2008 |
Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats.
Topics: Albuminuria; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2012 |
Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antihyperte | 2005 |
Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Antioxidants; Apolipoproteins E; Atherosclerosis; Cal | 2006 |
Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Aorta; Atherosclerosis; Benzimidazoles; Biphe | 2007 |
Blood flow-dependent arterial remodelling is facilitated by inflammation but directed by vascular tone.
Topics: Amlodipine; Animals; Blood Pressure; Female; Inflammation; Inflammation Mediators; Ligation; Macroph | 2008 |
A 56-year-old woman with sarcoidosis and acute renal failure.
Topics: Acute Kidney Injury; Amlodipine; Epoetin Alfa; Erythropoietin; Female; Fibrosis; Humans; Inflammatio | 2008 |